Abstract
Impaired proteasome function is a potential mechanism for dopaminergic neuron degeneration. To model this molecular defect, we administered systemically the reversible lipophilic proteasome inhibitor, carbobenzoxy-L-isoleucyl-γ-t-butyl-L-glutamyl-L-alanyl-L-leucinal (PSI), to rodents. In contrast to a previous report, this approach failed to cause any detectable behavioral or neuropathological abnormality in either rats or mice. Although theoretically appealing, this specific model of Parkinson's disease appears to exhibit poor reproducibility.
Original language | English (US) |
---|---|
Pages (from-to) | 260-264 |
Number of pages | 5 |
Journal | Annals of Neurology |
Volume | 60 |
Issue number | 2 |
DOIs | |
State | Published - Aug 2006 |
Externally published | Yes |
ASJC Scopus subject areas
- Neurology
- Clinical Neurology